TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02542813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM oxytocin 10 IU
Description: IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM oxytocin 10 IU
Description: IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH oxytocin 50 mcg
Description: IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH oxytocin 50 mcg
Description: IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH oxytocin 200 mcg
Description: IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH oxytocin 400 mcg
Description: IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH oxytocin 600 mcg
Description: IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
Study: NCT02058251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will self-administer a 40 IU dose of intranasal saline.
Study: NCT00191386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine hydrochloride
Description: 0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
Study: NCT03122249

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Advanced Cancer Symptom Management
Description: For a period of eight weeks patients will use the OASIS web-application daily to help them get better control of their cancer symptoms. In addition, to daily symptom and strategy tracking, participants will have eight e-visits with the nurse-coach via the Zoom application through the UIHC eHealth and eNovation Center to evaluate their progress with managing their symptoms, assess for barriers to implementing strategies, and offering coaching on how to improve symptom management. Questionnaires and blood samples will be collected at baseline (week 0) and follow-up (weeks 4, 8, and 12).
Study: NCT02873208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
Study: NCT00458367

Intervention type: DRUG
Intervention: Open label risperidone long acting injectable
Description: intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
Study: NCT01680939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 0.2-0.5 mg/kg PO q4h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10mg/kg PO q6hrs
Study: NCT05625880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place
Study: NCT01883219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKIs
Description: Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily. If the patients had T315I mutations, ponatinib will be given. If the BCR/ABL levels increased or did not decrease after one month's use of TKI, donor lymphocyte infusion will be given and the TKI drugs will be modulated. If the patients experienced hematologic relapse, they will withdraw from the study.
Study: NCT01394367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory and exercise therapy
Description: Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
Study: NCT01427114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, vincristine, and prednisolone
Description: 6 cycles of R-CVP followed by 2 cycles of rituximab
Study: NCT02915289

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Povidone Iodine
Description: Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
Study: NCT04720690

Intervention type: DEVICE
Intervention: Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output
Description: Measurement of arterial stiffness and cardiac output

Intervention type: DEVICE
Intervention: Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output
Description: Measurement of arterial stiffness and cardiac output

Intervention type: DEVICE
Intervention: Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output
Description: Measurement of arterial stiffness and cardiac output

Intervention type: DEVICE
Intervention: NICaS
Description: Measurement of cardiac output

Intervention type: DEVICE
Intervention: NICaS
Description: Measurement of cardiac output

Intervention type: DEVICE
Intervention: NICaS
Description: Measurement of cardiac output

Intervention type: DEVICE
Intervention: Echocardiography and ultrasound of arteries
Description: Measurement of cardiac output; measurement of intima-media thickness of arteries
Study: NCT00814164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative Study
Study: NCT01007097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
Study: NCT04720690

Intervention type: DEVICE
Intervention: Echocardiography and ultrasound of arteries
Description: Measurement of cardiac output; measurement of intima-media thickness of arteries

Intervention type: DEVICE
Intervention: Echocardiography and ultrasound of arteries
Description: Measurement of cardiac output; measurement of intima-media thickness of arteries
Study: NCT01048255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-765
Description: 300mg Oral Tablet, 900mg TID
Study: NCT00054418

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate
Description: calcium 600 mg daily administered orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium carbonate
Description: calcium 600 mg daily administered orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D
Description: vitamin D 400 U daily administered orally for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: vitamin D 400 U daily administered orally for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate sodium
Description: risedronate 35 mg weekly administered orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet weekly administered orally for one year
Study: NCT03551184

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline administered intravenously
Study: NCT04563572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPG Smartwatch
Description: Participants will then receive a PPG sensor in form of a smartwatch) model and will be instructed to wear them continuously for 48 hours. Simultaneously, a 48-hour Holter ECG will be performed. Start time on the PPG-sensor and the Holter ECG will be matched and continuous heart rhythm and -rate monitoring will be initiated. Patients will wear the devices over a 48-hour period of time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPG Smartwatch
Description: Participants will then receive a PPG sensor in form of a smartwatch) model and will be instructed to wear them continuously for 48 hours. Simultaneously, a 48-hour Holter ECG will be performed. Start time on the PPG-sensor and the Holter ECG will be matched and continuous heart rhythm and -rate monitoring will be initiated. Patients will wear the devices over a 48-hour period of time.
Study: NCT01007097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
Study: NCT02395289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Based Compassion Training (CBCT)
Description: Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health discussion
Description: Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
Study: NCT00092391

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live
Description: 0.5 mL subcutaneous injection of one of three sub-lots on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live
Description: 0.5 mL subcutaneous injection of one of three sub-lots on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live
Description: 0.5 mL subcutaneous injection of one of three sub-lots on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
Description: 0.5 mL subcutaneous injection on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
Description: 0.5 mL subcutaneous injection on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
Description: 0.5 mL subcutaneous injection on Day 0
Study: NCT03562624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY98-7443
Description: Active ingredient content (in mg IND/LNG):~low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY98-7443
Description: Active ingredient content (in mg IND/LNG):~low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY98-7443
Description: Active ingredient content (in mg IND/LNG):~low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonogestrel (Skyla, BAY86-5028)
Description: Comparative LNG dose
Study: NCT01332695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match
Study: NCT01574417

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control margarine
Description: Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant stanol-enriched margarine
Description: Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks.
Study: NCT04565236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1
Description: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.~The dose decisions are at the discretion of the investigator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2
Description: 12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.~\>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.~The dose decisions are at the discretion of the investigator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3
Description: 15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.~The dose decisions are at the discretion of the investigator.
Study: NCT02122055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sedation assessment
Description: Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sedation assessment
Description: Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screen of weaning
Description: 1. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screen of weaning
Description: 1. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
Study: NCT03105661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol Hydrochloride 200 mg
Description: Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIFEdipine 60 mg
Description: Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol 25 mg
Description: Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
Study: NCT01117805

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling intervention
Description: self-regulation telephone counseling program for African American women with asthma
Study: NCT02352649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovasculgen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovasculgen
Study: NCT02347462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)
Description: Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care according to the hospital severe asthma protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care according to the hospital severe asthma protocol
Study: NCT03250624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5024 0.3% cream
Description: Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.
Study: NCT01894555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81 mg daily for 4 weeks
Study: NCT01235338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDX + Venlafaxine XR
Description: * Day 1-5 LDX 30mg~* Day 6-10 LDX 50mg~* Day 11-15 LDX 70mg~* Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~* Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~* Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~* Day 31-34 Venlafaxine XR 150mg daily~* Day 35-38 Venlafaxine XR 75mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR + LDX
Description: * Day 1-5 Venlafaxine XR 75mg~* Day 6-10 Venlafaxine XR 150mg~* Day 11-15 Venlafaxine XR 225mg~* Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~* Day 21-25 Venlafaxine XR and LDX 50mg daily~* Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~* Day 31-34 Venlafaxine XR 150mg~* Day 35-38 Venlafaxine XR 75mg.
Study: NCT01844791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCZ103-OS
Description: OCZ103-OS is given in combination with chemotherapy each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Platinum is given as standard chemotherapy each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is given as standard chemotherapy each cycle